Feisu Bio Announces Completion of RMB 40 Million Financing to Advance Precision Oncology Solutions

VCBeat (WeChat ID: vcbeat) learned on the evening of September 20 that Xiamen Spacegen Co., Ltd. announced the completion of a new round of financing amounting to nearly RMB 40 million. This round was jointly participated by Jingxu Venture Capital, Jingyuan Lanhai, and Dongfang Yirui. The funds raised will be used to accelerate team building, research and development as well as certification of new products, and the establishment of marketing channels.

Spacegen & Jingxu Venture Capital / Jingyuan Lanhai

Xiamen Spacegen Co., Ltd. is an enterprise established under Xiamen’s “Double Hundred Plan” for leading entrepreneurial talents. Integrating R&D, production, sales, and services, the company is committed to providing products and solutions for precision oncology medicine. It has established a sound quality management system and obtained TÜV Rheinland ISO 13485 certification for medical device quality management systems.

Spacegen has secured national patents for its high-throughput sequencing library preparation technology, granted by the China National Intellectual Property Administration (CNIPA), as well as international PCT patents. Its “Library Preparation Kit for Gene Sequencing,” based on high-throughput sequencing technology, has obtained a Class I Medical Device Filing Certificate. Multiple products have received CE-IVD certification from the European Union. Furthermore, Spacegen’s “Human Tumor Multi-Gene Variant Detection Kit (Semiconductor Sequencing Method),” based on next-generation sequencing (NGS), was granted special approval for innovative medical devices by the China Food and Drug Administration (CFDA). In early 2016, the company completed a tens-of-millions RMB Series A financing round led by Qiaojing Capital. In the same year, it received a strategic Series A+ investment of tens of millions RMB from Darui Biology.

Jingxu Venture Capital, headquartered in Shanghai, is a venture capital firm focused on the healthcare sector. With extensive capabilities in industry resource integration, it is committed to value investing by identifying high-quality enterprises across the healthcare industry chain and facilitating their rapid growth. The medical funds under Jingxu Venture Capital’s management exceed RMB 1 billion. To date, it has invested in more than 20 high-growth healthcare companies, including Bowei Biology, BioNano, Laino Medical, and Antgene Biotechnology.

Jingyuan Lanhai is a venture capital firm jointly established by Jingrong Capital, Xiamen Venture Capital Co., Ltd., Xiamen Haicang Investment Group, and Lantao Asia Limited. With a fund under management of RMB 300 million, it invests in equity stakes of enterprises in the healthcare and other high-growth sectors, committed to promoting the development of local industries in Xiamen.

Orient Yirui (Shanghai) Investment Management Co., Ltd., jointly initiated by Orient International Group and Orient Securities, is a direct investment subsidiary fund of Orient Securities. The fund primarily focuses on investing in medical devices, the supply chain of pharmaceutical manufacturing and trading, healthcare services, and integrated medical and elderly care. Its investment scope covers stages from venture capital (VC) to private equity (PE), including projects aimed at exit through mergers and acquisitions. The company’s investment team consists of professionals from renowned industry investment institutions, bringing extensive expertise in medicine and finance, as well as substantial investment experience in the pharmaceutical sector. With access to broad project resources and a rigorous risk control system, the firm is committed to building a specialized, high-return investment fund for the healthcare and pharmaceutical industries.